Better Weight Loss Stock: Novo Nordisk Vs. Amgen

Industry Overview - The weight-loss market is one of the most active therapeutic areas in the pharmaceutical industry and is projected to continue growing significantly in the foreseeable future [1] Novo Nordisk - Novo Nordisk is a leader in the weight loss market with its GLP-1 drug, Wegovy, which is among the best-selling medicines in this niche [3] - The company has launched an oral version of Wegovy and has several promising pipeline candidates, including CagriSema, which has outperformed Wegovy in clinical studies and is under consideration for approval [3] - Novo Nordisk's market cap is $130 billion, with a current price of $38.58 and a gross margin of 80.90% [4][5] - The company is expanding its portfolio with candidates like amycretin, currently in phase 3 studies, and UBT251, which has shown strong efficacy in mid-stage trials in China [5] Amgen - Amgen currently does not have an approved weight loss medicine but is progressing with its leading candidate, MariTide, which is in phase 3 studies [6] - MariTide is being investigated for weight management, obstructive sleep apnea treatment, and cardiovascular outcomes, and could potentially earn approval within the next three years [8] - Amgen's market cap is $199 billion, with a current price of $369.47 and a gross margin of 70.47% [7][8] - MariTide's once-a-month administration could provide a competitive advantage over Wegovy, which is taken weekly, and it is estimated to generate $3.7 billion in sales by 2030 [8] Comparative Analysis - Novo Nordisk has a stronger portfolio and pipeline of weight loss products but is heavily reliant on its GLP-1 products for growth, facing market share losses to competitors like Eli Lilly [9] - Amgen has a more diversified portfolio, which may allow it to recover quickly even if it does not succeed in the weight-loss market [10] - While Novo Nordisk has more upside potential if its pipeline drugs succeed, its prospects are closely tied to the performance of its anti-obesity drugs, making it riskier [11] - Amgen is viewed as a safer investment option for exposure to the weight-loss market with limited downside risk [11]